Empagliflozin in newly untreated type 2 diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests a medication called empagliflozin (a type 2 diabetes pill) to see how well it works in people with type 2 diabetes who have not taken any diabetes drugs for at least 8 weeks. If you qualify, you may receive the study drug and help researchers learn more about managing blood sugar.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes and are not on any diabetes medications for at least 8 weeks.
- Your recent blood sugar test (HbA1c) is between 6.5% and 10.0%.
- You are between 20 and 75 years old.
- Your body mass index (BMI) is 18.5 to 39.9.
- You do not have certain serious heart, liver, kidney, or cancer problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different medicines (empagliflozin or semaglutide) added to your usual insulin to see if they help with blood sugar control and weight loss in people with type 1 diabetes who are overweight or have obesity. It may be a good fit if your diabetes is not well controlled with insulin injections alone.
This trial compares two diabetes medications, empagliflozin and glimepiride, added to your current treatment to see which is more effective and safe for managing blood sugar. It is for adults with type 2 diabetes who have already been on oral diabetes pills for at least 8 weeks.
This trial tests whether adding empagliflozin (a diabetes pill) to your current medicines (alogliptin and metformin) helps manage blood sugar better. It may be an option if your blood sugar is not well controlled with your current treatment.
This study is testing two different diabetes pills—dapagliflozin or pioglitazone—in people with type 2 diabetes. The goal is to see which one works better when added to your current metformin and DPP-4 inhibitor. You may qualify if your blood sugar is not well controlled with your current medications.
This trial tests two diabetes pills (pioglitazone and empagliflozin) to see if they can reduce liver fat in people with type 2 diabetes and fatty liver disease. It may help if your diabetes is not well controlled and you have a fatty liver confirmed by a special ultrasound scan.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
Hear when a new Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.